Entry Point Capital, LLC Cor Medix Inc. Transaction History
Entry Point Capital, LLC
- $246 Million
- Q3 2025
Shares
2 transactions
Others Institutions Holding CRMD
# of Institutions
206Shares Held
41.3MCall Options Held
1.33MPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA3.98MShares$45.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$40.3 Million0.0% of portfolio
-
Marshall Wace, LLP London, X03.47MShares$39.4 Million0.05% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.32MShares$37.7 Million0.74% of portfolio
-
State Street Corp Boston, MA1.84MShares$20.8 Million0.0% of portfolio
About CorMedix Inc.
- Ticker CRMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,208,200
- Market Cap $467M
- Description
- CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...